Items (Details) (USD $)	3 Months Ended		6 Months Ended
	Oct. 31, 2014	Oct. 31, 2013	Oct. 31, 2014	Oct. 31, 2013	Apr. 30, 2014	Jan. 26, 2014	Aug. 22, 2012	Dec. 08, 2011	Aug. 25, 2011
Details
Cash and cash equivalents held in PRC	$ 875,666		$ 875,666		$ 1,194,668
Cash and cash equivalents held in US	218		218		895
Allowance for Doubtful Accounts Receivable	1,148,547		1,148,547		1,143,550
Reserve for obsolete or slow-moving inventories	638,422		638,422		635,644
Taxes Payable, Current	56,396		56,396		69,298
Numerator for basic EPS, loss applicable to common stock holders	(274,914)	(957,836)	(779,118)	(1,543,210)
Weighted Average Number of Shares Issued, Basic	173,882,803	173,882,803	173,882,803	173,882,803
Weighted Average Number of Shares Outstanding, Diluted	173,882,803	173,882,803	173,882,803	173,882,803
Earnings Per Share, Basic	$ (0.002)	$ (0.006)	$ (0.004)	$ (0.009)
Earnings Per Share, Diluted	$ (0.002)	$ (0.006)	$ (0.004)	$ (0.009)
Foreign Currency Exchange Rate, Translation	6.13		6.13		6.16
Average exchange rates			6.16	6.16
Research and Development Expense	4,620	1,193	5,345	20,075
Shipping, Handling and Transportation Costs	56,035	46,539	138,812	118,236
Purchase price for apartment units held for sale									2,390,325
Payment of purchase price for apartment units held for sale								1,195,162	717,097
Investment in real estate held for resale	1,972,474		1,972,474		1,963,891
Inventory, Raw Materials, Gross	1,689,465		1,689,465		1,548,181
Inventory, Work in Process, Gross	176,113		176,113		44,898
Inventory, Finished Goods, Gross	2,884,310		2,884,310		2,295,930
Inventory, Gross	4,749,888		4,749,888		3,889,009
Reserve for obsolete inventory	(638,422)		(638,422)		(635,644)
Inventories, net	4,111,466		4,111,466		3,253,365
Office Equipment	62,378		62,378		58,266
Auto and Trucks	940,518		940,518		929,042
Machinery and Equipment, Gross	12,078,334		12,078,334		11,987,404
Buildings and Improvements, Gross	10,350,244		10,350,244		10,303,529
Construction in Progress, Gross	1,805,774		1,805,774		1,284,199
Property, Plant and Equipment, Gross	25,237,248		25,237,248		24,562,440
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	(10,650,970)		(10,650,970)		(9,624,082)
Property and equipment, net	14,586,278		14,586,278		14,938,358
Depreciation expense	370,869	446,949	981,661	897,034
Share issued for acquisition							7,666,666
Value of Shares issued for Acquisition							1,533,333
Cash paid for acquisition							92,541
Amortization of Acquired Intangible Assets			162,587	162,588
Only Sweet name rights and related technologies	587,183		587,183		587,183
Distribution agreement and related distribution channels	1,038,691		1,038,691		1,038,691
Finite-Lived Intangible Assets, Gross	1,625,874		1,625,874		1,625,874
Accumulated amortization of Intangible Assets	(704,546)		(704,546)		(541,959)
Finite-Lived Intangible Assets, Net	921,328		921,328		1,083,915
Land use right, gross	2,593,358		2,593,358		2,581,947
Accumulated amortization of Land Use Rights	(359,905)		(359,905)		(329,672)
LandUseRight	2,233,453		2,233,453		2,252,275
Amortization expense - Land use rights	14,359	14,365	28,685	28,651
Accounts receivable - related party	1,324,945		1,324,945		953,400
Revenue from Related Parties	1,054,439	590,680	1,940,047	1,733,991
Due to Pharmaceutical Corporation	181,280		181,280		248,873
Due to Qufu Shengwang	152,352		152,352		106,308
Total Due to Related Party	333,632		333,632		355,181
Working capital advances from related parties	46,044		46,044
Repayments from related parties	(68,729)		(68,729)
Effect of foreign currency exchange	1,136		1,136
Prepaid expenses and other current assets	2,221,798		2,221,798		1,192,649
Prepayments to suppliers	1,769,740		1,769,740		823,768
Employee advances and others	268,689		268,689		186,610
Deposits for Land Use Right	183,369		183,369		182,271
Grant funding received						1,146,921
Short-term Bank Loans and Notes Payable					811,794
Shares, Outstanding	173,882,803		173,882,803		173,882,803
Net revenues - Chinese Medicines	576,868	577,262	1,099,061	1,148,822
Net revenues - Chinese medicine - related party	0	0	0	0
Net revenues - Chinese medicine - Total	576,868	577,262	1,099,061	1,148,822
Net revenues - Stevioside - third party	2,396,023	1,656,015	4,824,731	2,658,050
Net revenues - Stevioside - related party	1,054,439	590,680	1,940,047	1,733,991
Net revenues - Stevioside - Total	3,450,462	2,246,695	6,764,778	4,392,041
Net revenues - Total segment and consolidated revenues	4,027,330	2,823,957	7,863,839	5,540,863
Interest income - Chinese Medicines	(14)	134	126	278
Interest income - Stevioside	(64,352)	(17,996)	(127,446)	(33,528)
Interest income - Total segment and consolidated interest expense	(64,366)	(17,862)	(127,320)	(33,250)
Depreciation and amortization - Chinese Medicines	20,383	23,557	39,372	46,033
Depreciation and amortization - Stevioside	446,138	519,051	1,133,561	1,042,240
Depreciation and amortization - Total segment and consolidated depreciation and amortization	466,521	542,608	1,172,933	1,088,273
Loss before taxes and noncontrolling interest - Chinese Medicines	33,361	(42,142)	57,477	(51,000)
Loss before taxes and noncontrolling interest - Stevioside	(247,850)	(843,764)	(679,457)	(1,467,270)
Loss before taxes and noncontrolling interest - Corporate and other	(17,030)	(71,930)	(86,211)	(24,940)
Income (loss) before income taxes - Total segment and consolidated depreciation and amortization	(231,519)	(957,836)	(708,191)	(1,543,210)
Segment assets- Chinese Medicines	647,545		647,545		605,918
Segment assets-Stevioside	13,938,733		13,938,733		14,332,440
Segment assets-Corporate and other	0		0		0
Segment assets-Total consolidated assets	14,586,278		14,586,278		14,938,358
Investment in real estate held for resale	1,972,474		1,972,474		1,963,891
Deposits in PRC	$ 875,666		$ 875,666